delivered net profit of $276.7 million, an increase of 13 per cent on FY18, which includes $10.8 million in non-cash net gains from the revaluation of innovation fund investments.
Operating cash flow increased by $37.9 million to $296.0 million and the Board has declared a final dividend of $1.75, an increase of 9 per cent.
Cochlear implant units down 3 per cent, with developed markets in line with FY18 but emerging market volumes declined.
The US and Germany lost market share following a competitor product launch.
Full year dividends increased by 10 per cent to $3.30 in FY19, fully franked.
Shares in Cochlear (ASX:COH)
are trading 1.48 per cent higher at $204.51.